Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the long-term safety and efficacy of ibrutinib monotherapy in patients with previously treated Waldenström’s macroglobulinemia (WM), including those with MYD88 and CXCR4 mutations. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.